Abstract:Purpose To evaluate the efficacy of a subthreshold micropulse laser (SML) in patients with central serous chorioretinopathy (CSCR). Methods Retrospective clinical study conducted at the Departments of Ophthalmology at a university and a municipal hospital in Zurich, Switzerland. We enrolled acute and chronic CSCR patients with persistent subretinal fluid (SRF) treated with SML. Two treatment protocols (fluorescein/indocyanine green angiography or optical coherence tomography guided) were evaluated for efficacy after 3 and 6 months. The primary outcomes of the study were reduction and percentage of eyes with complete resolution of SRF 3 and 6 months after SML treatment. Secondary endpoints included changes in central subfield thickness (CST) and visual acuity (VA) after 3 and 6 months. Results The study involved 37 eyes (35 patients, 48.6% chronic). A statistically significant reduction in SRF height and CST could be shown, irrespective of SRF duration, type of CSCR, or chosen guidance after 3 and 6 months: SRF − 40 μm (p < 0.01), CST − 52 μm (p 0.05). Conclusion The effectiveness of SML in CSCR is under continuous debate. Our study findings demonstrate structural but only little functional changes with SML. In view of the shortage of verteporfin for photodynamic therapy, SML remains an important therapeutic option for CSCR patients. Zweck Die Effektivität der Subthreshold Micropulse-Lasertherapie (SML) bei Patienten mit Chorioretinopathia centralis serosa (CRCS) zu bewerten. Patienten und Methoden Eine retrospektive klinische Studie, durchgeführt an den Augenkliniken des Universitätsspital Zürich und des Stadtspital Zürich, Schweiz. Akute und chronische CRCS-Patienten mit persistierender subretinaler Flüssigkeit (SRF), die mit SML behandelt wurden, wurden eingeschlossen. Zwei Behandlungsprotokolle (Fluoreszein/Indocyanin-Grün-Angiographie oder optische Kohärenztomographie) wurden auf ihre Wirksamkeit nach 3 und 6 Monaten hin untersucht. Der primäre Endpunkt der Studie war die Reduktion der SRF und der Prozentsatz der Augen mit vollständiger Auflösung der SRF 3 und 6 Monate nach der SML-Behandlung. Sekundäre Endpunkte umfassten Veränderungen der Central Subfield Thickness (CST) und des Visus (VA) nach 3 und 6 Monaten. Ergebnisse Die Studie umfasste 37 Augen (35 Patienten, 48,6% chronisch). Eine statistisch signifikante Reduktion der SRF-Höhe und CST konnte unabhängig von der Dauer der SRF, dem CRCS-Typ oder des Behandlungsprotokoll nach 3 und 6 Monaten gezeigt werden: SRF − 40 μm (p < 0,01), CST − 52 μm (p 0,05). Konklusion Die Wirksamkeit von SML bei CRCS ist Gegenstand anhaltender Diskussion. Die Ergebnisse unserer Studie zeigen statistisch signifikante strukturelle, aber nur geringfügige funktionelle Veränderungen durch SML. Angesichts des Mangels an Verteporfin für die photodynamische Therapie bleibt SML eine wichtige therapeutische Option für CSCR-Patienten. * These authors share the first authorship. ** These authors share the last authorship. Received: 29 October 2023 Accepted: 12 December 2023 Article published online: 23 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Crossover to 689 nm laser therapy after poor responsiveness to subthreshold micropulse laser for chronic central serous chorioretinopathy

Comparison of two laser power levels in the subthreshold MicroPulse Yellow Laser Treatment of Acute Central Serous Chorioretinopathy

Efficacy of 577 Nm Subthreshold Micropulse Laser in Central Serous Chorioretinopathy

Subthreshold Micropulse Laser (577 nm) Therapy with an Individual Approach for Power Titration in Patients with Chronic Central Serous Chorioretinopathy (Pilot Study)

A randomized non-inferiority trial of 577nm subthreshold micropulse laser versus half-dose photodynamic therapy for acute central serous chorioretinopathy

532 nm versus 810 nm subthreshold micropulse laser in treatment of non-resolving central serous chorioretinopathy: A randomized controlled trial

Prognostic factors of visual outcome in central serous chorioretinopathy treated with subthreshold micropulse laser therapy

Subthreshold Continuous Wave Autofluorescence-controlled Laser Treatment of Chronic Central Serous Chorioretinopathy

Extensive Submacular Haemorrhage in Polypoidal Choroidal Vasculopathy Managed by Sequential Gas Displacement and Photodynamic Therapy: a Pilot Study of One‐year Follow Up

Treating the central serous chorioretinopathy with 532nm green laser

Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study

Effectiveness, Safety and Choroidal Changes of a Fovea-Sparing Technique for the Treatment of Chronic Central Serous Chorioretinopathy with Yellow Subthreshold Laser

Efficacy of Subthreshold Micropulse Laser for Central Serous Chorioretinopathy

Functional and anatomical results of subthreshold micropulse laser as rescue treatment for central serous chorioretinopathy after verteporfin shortage

Six-Month Results of 577 nm Subthreshold Micropulse Laser Therapy in Non-center Involving Diabetic Macular Edema

Visual and anatomical evaluation of navigated subthreshold micropulse laser versus photodynamic therapy in managing chronic central serous chorioretinopathy

Fluorescein angiography patterns and subretinal hyperreflective material predict subthreshold micropulse laser response in chronic central serous chorioretinopathy

Effect of Focal Laser Photocoagulation on the Ganglion Cell Complex Thickness in Acute Central Serous Chorioretinopathy

Safety and efficacy of subthreshold micropulse yellow laser for persistent subretinal fluid after scleral bucking a randomized clinical trial

[Observation on Long-Term Efficacy of Half-Dose Photodynamic Therapy with Chronic Central Serous Chorioretinopathy Using Optical Coherence Tomography].

Micropulse Laser versus Eplerenone for Chronic Central Serous Chorioretinopathy: A 12-Month Comparison